Cyclosquaramides as kinase inhibitors with anticancer activity
Priam Villalonga1, Silvia Fernández de Mattos, Guillem Ramis
1Institut Universitari d'Investigació en Ciències de la Salut, Universitat de les Illes Balears, Carretera Valldemossa km 7.5, Spain.
Chemmedchem
|July 11, 2012
Summary
New macrocyclic oligosquaramides show potent anticancer activity by inhibiting key kinases. Their effectiveness and selectivity depend on cell type, highlighting the importance of the macrocyclic structure for antitumor effects.
Area of Science:
- Medicinal Chemistry
- Cancer Biology
- Pharmacology
Background:
- Oligosquaramide derivatives are explored for therapeutic potential.
- Macrocyclic structures are increasingly investigated for drug development.
Purpose of the Study:
- To synthesize and evaluate novel oligosquaramide-based macrocycles as anticancer agents.
- To investigate the mechanism of action and structure-activity relationships of these compounds.
Main Methods:
- Synthesis of a series of oligosquaramide-based macrocycles.
- Biological evaluation using the NCI-60 human tumor cell line panel.
- Kinase inhibition assays to identify molecular targets.
Main Results:
- Compound 7 demonstrated significant antiproliferative activity (1-10 μM IC50) against the NCI-60 panel.
- Anticancer activity showed cell-type selectivity.
- Compounds 7 and 8 inhibited multiple kinases, including ABL1, CDK4, CHK1, PKC, c-MET, and FGFR.
- Acyclic and smaller cyclic analogs lacked antitumor activity.
Conclusions:
- Macrocyclic oligosquaramides represent a promising class of anticancer agents.
- The macrocyclic structure and specific molecular size are crucial for antitumor efficacy.
- Inhibition of protein phosphorylation via key kinases is a likely mechanism of action.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
00:50Anaphase Promoting Complex
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...